The association of chronic kidney disease complications by albuminuria and glomerular fltration rate: A cross-sectional analysis

Clinical Nephrology

Volumn 80, Issue 1, 2013, Pages 29-39

  Viswanathan, Gautham ^a   Sarnak, Mark J ^a   Tighiouart, Hocine ^a   Muntner, Paul ^b   Inker, Lesley A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Albuminuria; Chronic kidney disease; Complications; Glomerular fltration rate

Indexed keywords

ALBUMIN; CREATININE;

ACIDOSIS; ADULT; ALBUMINURIA; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN URINE LEVEL;

ACIDOSIS; ADULT; AGED; ALBUMINURIA; ANEMIA; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84880657072     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107842     Document Type: Article

References (43)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am J Kidney Dis. 2002; 39 (Suppl 1): S1-S266.
2. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006; 333: 1047.
3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164: 659-663.
4. Drey N, Roderick P , Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003; 42: 677-684.
5. Hillege HL, Fidler V , Diercks G F , van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777-1782.
6. Astor BC, Hallan SI, Miller ER III, Yeung E, Coresh J. Glomerular fltration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008; 167: 1226-1234.
7. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008; 23: 3851-3858.
8. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albu-minuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009; 20: 1069-1077.
9. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, Gansevoort R T, Kasiske BL, Eckardt KU. The defnition, classifcation and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2010.
10. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Ka-siske BL, Wright J et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomer-ular fltration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011; 79: 1331-1340.
11. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort R T, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Ganse-voort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular fltra-tion rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011; 79: 1341-1352.
12. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, Jong PE, Coresh J, de Jong PE, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Wang Y, Atkins RC, Polkinghorne KR et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011; 80: 93-104.
13. Tonelli M, Muntner P, Lloyd A, Manns BJ, James M T, Klarenbach S, Quinn RR, Wiebe N, Hemmel-garn BR; Alberta Kidney Disease Network. Using proteinuria and estimated glomerular fltration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011; 154: 12-21.
14. Klahr S, Levey AS, Beck GJ, Caggiula A W, Hun-sicker L, Kusek J W, Striker G; Modifcation of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994; 330: 877-884.
15. Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluchter MD, Williams GW; The Modifcation of Diet in Renal Disease Study Group. Design and statistical issues of the Modi-fcation of Diet in Renal Disease Trial. Control Clin Trials. 1991; 12: 566-586.
16. Greene T, Bourgoignie JJ, Habwe V, Kusek J W, Snetselaar LG, Soucie JM, Yamamoto ME. Baseline characteristics in the Modifcation of Diet in Renal Disease Study. J Am Soc Nephrol. 1993; 4: 1221-1236.
17. Kusek J W, Coyne T, de Velasco A, Drabik MJ, Fin-lay RA, Gassman JJ, Kiefer S, Powers SN, Stein-man TI. Recruitment experience in the full-scale phase of the Modifcation of Diet in Renal Disease Study. Control Clin Trials. 1993; 14: 538-557.
18. National Kidney Disease Education Program. Health Professionals Chronic Kidney Disease (CKD) Information. 2011. http://www.nkdep.nih.gov/professionals/chronic_kidney_disease.htm#diagnosis.
19. Hostetter TH, Lising M. National kidney disease education program. J Am Soc Nephrol. 2003; 14 (Suppl 2): S114-S116.
20. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol. 2006; 17: 2120-2126.
21. Stoycheff N, Stevens LA, Schmid CH, Tighiouart H, Lewis J, Atkins RC, Levey AS. Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the defnition. Am J Kidney Dis. 2009; 54: 840-849.
22. Chronic kidney disease: National clinical guideline for early identifcation and management in adults in primary and secondary care. In: Royal College of Physicians. London: National Collaborating Centre for Chronic Conditions; 2008. http://guidance.nice.org.uk/CG73/Guidance/pdf/English.
23. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007; 50: 471-530.
24. Buckalew VM J r, Berg RL, Wang S-R, Porush JG, Rauch S, Schulman G; Modifcation of Diet in Renal Disease Study Group. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modifcation of diet in renal disease study baseline cohort. Am J Kidney Dis. 1996; 28: 811-821.
25. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47: S1-S146.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201.
27. Kidney Disease Outcomes Quality Initiative (K/ DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43 (Suppl 1): S1-S290.
28. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modifcation of Diet in Renal Disease Study. Ann Intern Med. 1995; 123: 754-762.
29. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; S1-S130.
30. Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and pro-teinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004; 44: 806-814.
31. Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD. Association of single measurements of dipstick proteinuria, estimated glomerular fltration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006; 17: 1444-1452.
32. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gan-sevoort RT; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular fltration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073-2081.
33. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, De Santo NG. Low glomerular fltra-tion in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006; 70: 800-806.
34. Ochodnicky P, Henning RH, van Dokkum R P, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol. 2006; 47 Suppl 2: S151-162.
35. de Zeeuw D, Parving HH, Henning RH. Microal-buminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006; 17: 2100-2105.
36. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner SM. Infammation and microal-buminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000; 58: 1703-1710.
37. Tsioufs C, Dimitriadis K, Stefanadis C, Kallika-zaros I. The emerging role of subclinical infam-mation in hypertension-associated early renal dysfunction: focus on microalbuminuria. Hellenic J Cardiol. 2006; 47: 361-365.
38. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis. 2001; 38: 1-8.
39. Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant. 2004; 19: 277-281.
40. Jafar TH, Stark PC, Schmid CH, Landa M, Mas-chio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level me-ta-analysis. Ann Intern Med. 2003; 139: 244-252.
41. National Kidney Disease Education Program. Estimation of Kidney Function for Medication Dosage Prescriptions in Adults. 2009. http://www.nk-dep.nih.gov/.
42. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. Am J Kidney Dis. 2006; 48: S1-S322.
43. Maack T, Johnson V, Kau S T, Figueiredo J, Sig-ulem D. Renal fltration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979; 16: 251-270